Form 4: Oncotelic Therapeutics CEO Increases Stake with Significant Share Purchases

Oncotelic Therapeutics, Inc. CEO and Chairman, Vuong Trieu, has increased his direct beneficial ownership in the company through open market purchases of common stock.

Summary

• Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, Inc. (OTLC), reported open market purchases of the company's common stock between July 8, 2025, and July 10, 2025.
• A total of 198,737 shares were acquired directly across three transactions.
• The reported purchase price in Table I is $0.005 per share, however, the remarks section states the shares were purchased at $0.05 per share.
• Following these transactions, Dr. Trieu's direct beneficial ownership stands at 93,293,560 shares.
• Additionally, Dr. Trieu has indirect beneficial ownership of 16,780,384 shares through Autotelic, Inc. and 6,872,529 shares through his spouse.

Sentiment

Score: 7

Explanation: Insider buying by the CEO and Chairman is generally a positive signal, indicating management's confidence in the company's prospects. The discrepancy in the reported purchase price is a minor negative, but the overall sentiment leans positive due to the insider's increased stake.

Positives

• CEO and Chairman Vuong Trieu increased his direct stake in Oncotelic Therapeutics, Inc. through open market purchases, signaling confidence in the company's future prospects.
• The acquisition of 198,737 shares by a key insider demonstrates a commitment to the company's valuation.

Negatives

• A significant discrepancy exists between the reported purchase price in Table I ($0.005 per share) and the price stated in the remarks section ($0.05 per share), which could cause confusion regarding the actual transaction value.
• There is a minor discrepancy between the sum of individual share purchases (198,737 shares) and the total shares stated as purchased in the remarks section (198,937 shares).

Future Outlook

No forward-looking statements or guidance are provided in this document, which is a report of insider transactions.

Industry Context

This document reports an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• Indirect beneficial ownership includes 16,780,384 shares held by Autotelic, Inc., which is likely a related entity.
• Indirect beneficial ownership includes 6,872,529 shares held by the reporting person's spouse.

Stakeholder Impact

• Shareholders: May view the insider purchases as a positive signal of management confidence, potentially influencing stock price positively.

Key Dates

Recommendation

Keywords

Oncotelic Therapeutics, OTLC, insider trading, Form 4, beneficial ownership, share purchase, CEO, Chairman, Director, stock acquisition